Drosophila SPARC Is a Self-Protective Signal Expressed by Loser Cells during Cell Competition  by Portela, Marta et al.
Developmental Cell
ArticleDrosophila SPARC Is a Self-Protective
Signal Expressed by Loser Cells
during Cell Competition
Marta Portela,1,5 Sergio Casas-Tinto,1,5 Christa Rhiner,1,4,5 Jesu´sM. Lo´pez-Gay,1 Orlando Domı´nguez,2 Davide Soldini,3,*
and Eduardo Moreno1,4,*
1Molecular Oncology Programme
2Biotechnology Programme
Spanish National Cancer Centre (CNIO), Melchor Ferna´ndez Almagro, 3, Madrid 28029, Spain
3Institute of Surgical Pathology, University Hospital Zurich, CH-8091 Zurich, Switzerland, Switzerland
4Institute of Cell Biology, University of Bern, Baltzerstrasse CH-3012 Bern, Switzerland
5These authors contributed equally to this work
*Correspondence: davide.soldini@usz.ch (D.S.), emoreno@cnio.es or eduardo.moreno@izb.unibe.ch (E.M.)
DOI 10.1016/j.devcel.2010.09.004SUMMARY
During development and aging, animals suffer
insults that modify the fitness of individual cells. In
Drosophila, the elimination of viable but suboptimal
cells is mediated by cell competition, ensuring that
these cells do not accumulate during development.
In addition, certain genes such as the Drosophila
homolog of human c-myc (dmyc) are able to trans-
form cells into supercompetitors, which eliminate
neighboring wild-type cells by apoptosis and over-
proliferate, leaving total cell numbers unchanged.
Here we have identified Drosophila Sparc as an early
marker transcriptionally upregulated in loser cells
that provides a transient protection by inhibiting Cas-
pase activation in outcompeted cells. Overall, we
describe the unexpected existence of a physiological
mechanism that counteracts cell competition during
development.
INTRODUCTION
During their lifetime, cells of multicellular animals can suffer
insults (mutations, transient errors, infections, oxidative damage)
that may compromise their fitness (Weinberg, 2007). In Dro-
sophila there are mechanisms (i.e., ‘‘cell competition’’) that
seem to recognize and eliminate less adapted or weaker cells
of developmental primordia, ensuring that viable but suboptimal
cells do not accumulate during development or aging. How
groups of cells compare their relative fitness levels and decide
which cell will remain in the tissue (‘‘winner cell’’) and which
cell will die (‘‘loser cell’’) is not completely clear. However, recent
work in the Drosophila imaginal discs has shown that cell
competition is a multistep process where at least six steps can
be identified:
First, an insult (i.e., mutation in Minutes [Morata and Ripoll,
1975; Simpson, 1979; Moreno et al., 2002a]) or dmyc (Moreno562 Developmental Cell 19, 562–573, October 19, 2010 ª2010 Elsevand Basler, 2004; de la Cova et al., 2004) increases or decreases
the fitness of a particular cell within the imaginal disc epithelium.
Second, this translates into imbalances in morphogen and
survival factor signaling (i.e., differences in signaling levels of
the BMP2/4 homolog Decapentaplegic [Dpp]) (Adachi-Yamada
et al., 1999; Adachi-Yamada and O’Connor, 2002; Moreno
et al., 2002a). Third, different isoforms of the cell membrane
protein Flower (Fwe) (Rhiner et al., 2010; Yao et al., 2009) label
cells as winners or losers (Rhiner et al., 2010). Due to this role
in distinguishing winners from losers, the gene was also called
flower after the so-called ‘‘Flower war’’ between the Aztecs
and their neighbors (Hassig, 1988). This was a peculiar type of
ancient war where, likewise, losers were not killed immediately
but rather captured, marked as ‘‘losers’’ with blue paint, and
eventually sacrificed later during an independent ritual (Moreno,
2010; Hassig, 1988). In Drosophila the fwe locus produces
three isoforms: Fweubi, FweLose-A, and FweLose-B. Basal levels
of Fweubi are constantly produced in the wing imaginal disc,
but during cell competition the loser cells downregulate fweubi,
and the two fweLose isoforms are upregulated (Rhiner et al.,
2010). Fourth, the expression of fweLose transcripts ultimately
leads to Caspase activation in the ‘‘loser’’ cell (Moreno et al.,
2002a; Rhiner et al., 2010). Fifth, weak Caspase activation in
the loser cell activates an engulfment response in the winner
cell, which is believed to help killing the outcompeted loser cell
(Baker and Li, 2008; Li and Baker, 2007), and/or accompanies
its extrusion from the epithelial layer (Moreno and Basler,
2004). Finally, this process results in a type of proliferation, where
the winner cells proliferate to replace the loser cells. This type of
proliferation requires the killing of the surrounding cells and has
been termed ‘‘apoptosis-dependent proliferation’’ (Moreno,
2008).
Certain genes, especially theDrosophila homolog of the proto-
oncogene c-myc, dmyc, are able to transform cells into super-
competitors (Moreno and Basler, 2004), which are able to elimi-
nate neighboring wild-type (wt) cells by apoptosis. Because the
expansion of the supercompetitor cells by ‘‘apoptosis-depen-
dent proliferation’’ occurs at the expense of normal surrounding
cells, no morphological defects become apparent because total
cell numbers remain unchanged (Moreno and Basler, 2004).ier Inc.
Figure 1. Loser Cells Upregulate dSPARC during Cell Competition
(A and B) wt (A) and (B) Minute heterozygous (M/+) (B) control wing discs stained with anti-dSPARC (red), showing uniform expression. Inset in B shows a wing
disc heterozygous for the Minute mutation marked by GFP (M,ubi-GFP).
(C and D) M+ (wt) clones in a M/+ background. dSPARC (red) is upregulated in M/+ cells (green).
(E and F) Control discs showing endogenous expression of dSPARC (red) both in wt (E) and tub > dmyc (F) wing epithelia.
(G and H) wt clones (green) in a tub > dmyc background upregulate dSPARC (red).
(I and J) lglmutant clones (green) show increased dSPARC expression (red). The clone boundaries are outlined in white color. (K) There are white arrows pointing
to the small brk-overexpressing clones.
(K and L) brk overexpressing clones (green) in a wt background show upregulation of dSPARC (red). (K) There are white arrows pointing to the small
brk-overexpressing clones. Inset in K and L (K0 and L0) show a magnification of the UAS-brk clones.
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dSPARC Protects Loser Cells from Cell CompetitionTherefore, it has been proposed that supercompetition and
apoptosis-dependent proliferation could play an important role
in early stages of cancer and the formation of ‘‘cancerization
fields,’’ which occur in the absence of morphological malforma-
tions (Moreno, 2008; Rhiner and Moreno, 2009). It has also been
proposed that this function of d-myc regulates organ size (de la
Cova et al., 2004).
We have identified dsparc, the Drosophila homolog of the
SPARC/Osteonectin protein family (Martinek et al., 2008), as
an early marker that is transcriptionally upregulated in loser
cells during cell competition. SPARC, a secreted multifunctional
glycoprotein, belongs to the family of matricellular proteins,
which modulate cell-cell and cell-matrix interactions and are
induced during morphogenesis, development, tissue injury,
and tissue remodeling (Clark and Sage, 2008). Mammalian
SPARC is known to bind several ECM proteins and modulate
the activity of various growth factors/chemokines (TGF-b,
VEGF, etc.). It has been mainly found to function in de-adhesion,
anti-proliferation and regulation of the ECMproduction (Framson
and Sage, 2004). Studies of tumor growth in SPARC null mice
point to a role of SPARC in tumor/stromal cell interactions
(Brekken et al., 2003; Sangaletti et al., 2003), but the effects on
tumor growth are controversial and poorly understood becauseDevelopmSPARC was found to restrict as well as promote tumor growth
and metastasis (Framson and Sage, 2004; Arnold and Brekken,
2009). For example, humans have three different dSPARC
homologs: SPARC/Osteonectin, SPARC-like protein 1, and Fol-
listatin-like protein among which SPARC/Osteonectin is best
studied (Clark and Sage, 2008). SPARC has been clearly impli-
cated in tumor development, but published reports suggest
diverse and contradictory functions: SPARC shows differential
expression in many epithelial malignancies (prostate, lung, intes-
tine) (Clark and Sage, 2008) and can promote tumor develop-
ment (Puolakkainen et al., 2004; Sansomet al., 2007), metastasis
(Minn et al., 2005), or field cancerization (Brabender et al., 2005),
whereas in other cases SPARC also shows characteristics of
a tumor suppressor in many cancers (Brune et al., 2008; Chee-
tham et al., 2008; Hong et al., 2008; Rodriguez-Jimenez et al.,
2007; Sato et al., 2003; Socha et al., 2009; Sova et al., 2006;
Suzuki et al., 2005; Wang et al., 2005; Yang et al., 2007). There-
fore, howSPARC functionsmechanistically in tumorigenesis and
metastasis still remains elusive.
Here we describe the existence of a physiological mechanism
that counteracts cell competition. We show that transcriptional
activation of dsparc protects cells against cell-to-cell differences
in cellular fitness, setting a higher threshold for Caspaseental Cell 19, 562–573, October 19, 2010 ª2010 Elsevier Inc. 563
Figure 2. dSPARC Is a Specific Marker of Cell Competition
(A and B) GFP-marked cells next to pten mutant clones (absence of green) do not show dSPARC upregulation (red).
(C and D) hid-overexpressing clones (green) in a wt background do not present enhanced dSPARC expression (red). Insets in C0 and D0show a magnification of
dSPARC staining and GFP clones (arrows).
(E) hepCA overexpressing clones (green) in a wt background do not show upregulation of dSPARC (red). (E0) Nuclei are stained with DAPI (blue). (E00) dSPARC
staining is shown in red. (E00 0) Merge. (E00and E00 0) There are white arrows pointing to the small GFP clones.
(F) egr-overexpressing clones (green) in awt background do not show increased dSPARC levels (red). (F0) Anti-HA staining to visualize HA-egr expressing clones
in magenta. (F00) dSPARC staining (red). (F00 0) merge (There are white arrows pointing to the small GFP clones).
(G and H) hid-overexpressing clones (green) during 24 hr under the control of Gal 80ts in a wt background do not show upregulation of dSPARC (red).
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dSPARC Protects Loser Cells from Cell Competitionactivation in loser cells. This mechanism allows useful cells to
recover from transient and limited stress before they are unnec-
essarily eliminated by their neighbors. Moreover, we show that
dSPARC also protects Drosophila S2 cells from serum with-
drawal-induced apoptosis by inhibiting a secreted killing signal
(KS). The here-described functions of Sparc in Drosophila may
help to understand the complex behavior of human and mouse
Sparc at tumor-host borders.
RESULTS
We performed gene expression microarray analysis to identify
new molecular determinants and markers in the multistep
process of cell competition. We compared the transcriptional
profile of imaginal discs where cell competition was induced to
control samples where no cell competition occurred (Rhiner
et al., 2010; see Experimental Procedures). Among the genes
that were differentially expressed (see Figure S1A available
online), we found CG6378, which encodes for a protein with
a signal peptide (Figure S1B) that was transcriptionally upregu-
lated very early during cell competition. CG6378 is the Dro-
sophila homolog of mammalian SPARC proteins (Martinek
et al., 2008).
dSPARC Is Upregulated during Several Forms of Cell
Competition and Supercompetition
We generated specific antibodies against Drosophila Sparc
(dSPARC) and tested them in several settings where cell compe-
tition is known to occur. First, we used theMinute (M) technique,564 Developmental Cell 19, 562–573, October 19, 2010 ª2010 Elsevconfronting M/+ loser cells, heterozygously mutant for a ribo-
somal protein gene, with wt winner cells (Morata and Ripoll,
1975; Simpson, 1979). Imaginal discs formed entirely by wt
(Figure 1A) orM/+ cells (Figure 1B) (i.e., in the absence of compe-
tition) expressed similar low levels of dSPARC. In contrast,
clones of M/+ loser cells growing in the same disc with wt cells
showed upregulated dSPARC (Figures 1C and 1D). Next, we
repeated antibody stainings in a supercompetitor assay: It has
been previously shown that cells expressing higher levels of
dMyc under the tubulin promoter (tub > dmyc) can outcompete
neighboring wt cells, which in this setting perform as loser cells
(Moreno and Basler, 2004; de la Cova et al., 2004). To this end,
wt cells (tub > G4) were generated next to dMyc-overexpressing
supercompetitors (tub > dmyc) by a heat-shock-inducible
Flipase that recognizes a dmyc cassette flanked by FRT sites
in tub > dmycSTOP > G4 transgenic flies. Resulting wt cells
are marked by GFP by including a UAS-GFP transgene that is
activated upon Gal4 binding. Again, we first analyzed discs
without competition, composed homogenously by wt or tub >
dmyc cells and detected comparable low levels of dSPARC
(Figures 1E and 1F). However, in discs where clones of wt cells
were mixed with tub > dmyc cells, dSPARC was upregulated
in the wt loser cells (Figures 1G and 1H). Then, we used a third
setting where cell competition has been described: lethal-
giant-larvae (lgl/) clones, like scribble or dlg mutant cells,
behave as loser cells when confronted with wt cells (Agrawal
et al., 1995; Brumby and Richardson, 2005; Hariharan and
Bilder, 2006; Igaki et al., 2009; Cordero et al., 2010). Also in
this case, dSPARC expression was increased in the loser lgl/ier Inc.
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dSPARC Protects Loser Cells from Cell Competitioncells (Figures 1I and 1J). Finally, we tested a fourth competition
scenario where brinker overexpressing clones behave as loser
cells when confronted with wt cells in the wing pouch (Moreno
et al., 2002a). Once more, dSPARC expression was increased
in the brk overexpressing loser cells (Figures 1K and 1L). These
results suggest that dSPARC is upregulated in cells that are sub-
jected to cell competition.
dSPARC Levels Specifically Increase Upon
Cell Competition
Upregulation of dSPARC could be provoked by other cell inter-
actions than competition. To answer this question, we generated
pten mutant clones as a control, which overproliferate without
inducing cell competition (Rhiner et al., 2009), and we observed
that cells next to pten mutant clones did not show upregulation
of dSPARC protein (Figures 2A and 2B). To know whether
dSPARC is specifically activated by cell competition or may
form part of a general response to inducers of apoptosis, we
generated clones that overexpress the pro-apoptotic gene hid
under the control of the actin promoter in a wt background.
Such hid-overexpessing clones that are removed by apoptosis
(Grether et al., 1995) did not show increased dSPARC levels
(Figures 2C and 2D). Next, we used yet a different approach to
induce apoptosis in clones in the absence of cell competition.
We activated JNK in GFP-marked clones by overexpressing
a constitutively active form of hemipterous (hep) (Glise et al.,
1995; Adachi-Yamada et al., 1999), the kinase that activates
JNK, in a wt background. hep clones that are eliminated by
apoptosis show no upregulation of dSPARC protein (Figure 2E).
In addition, we generated eiger (egr)-overexpressing clones in
awt background because it is known that egr induces cell death
independent of cell competition (Igaki et al., 2002; Moreno et al.,
2002b). We observed that also in this case there is no upregula-
tion of dSPARC in the egr-expressing clones undergoing cell
death (Figure 2F). Finally, we generated large clones that overex-
pressed hid. To achieve this we used a Gal80ts (McGuire et al.,
2003) that at 17C blocks Gal4 and, therefore, Hid production.
Initially, we let the clones grow for 72 hr at the restrictive temper-
ature (17C). Afterwards we observed that the large clones
disappeared when shifted to the permissive temperature
(29C, that inactivates Gal80ts and allows Hid production)
without any upregulation of dsparc (Figures 2G and 2H). These
data provide evidence that dSPARC is a specific marker of cell
competition (Figure 1) and not a general marker of apoptosis
(Figure 2).
Early Upregulation of dSPARC Is Dependent
on Dpp Signaling
According to the microarray data, dsparc was expressed early
on (12 hr after induction of cell competition) and maintained in
many cells (in leg, wing, and eye imaginal discs [data not
shown]). Indeed, abundant dsparc transcripts could be detected
by mRNA FISH in loser cells 48 hr after clone induction (ACI),
confirming the results of the microarray (Figures 3A and 3B).
To our knowledge dSPARC is, therefore, the most reliable
marker for cell competition, detectable at transcriptional and
translational levels (Figures 1 and 3) because differential expres-
sion of downstream components of the Dpp pathway (pMad,
Brinker) remains difficult to uncover (Moreno et al., 2002a;DevelopmMoreno and Basler, 2004), and Caspase activation occurs only
in few cells at late stages of the competition process (Moreno
et al., 2002a; Baker and Li, 2008).
For epistasis analysis we checked if Caspase activation is
required for dSPARC upregulation. For this purpose wemodified
the previously described supercompetitor assay by blocking
Caspase activation specifically in GFP-marked loser cells either
with UAS-p35 (a baculovirus inhibitor of active Caspases [Hay
et al., 1994]) or UAS-dIAP1 (the Drosophila inhibitor of apoptosis
protein 1 [Yoo et al., 2002]), which are activated by Gal4 after
flip-out of the dmyc stop cassette. Inhibition of Caspase activity
by dIAP1 and p35 had no effect on dSPARC induction upon
competition 72 hr ACI (Figures 3C–3F), demonstrating that Cas-
pase activation is not required for high dSPARC levels in loser
cells. This is consistent with the observations that dSPARC is
an early marker of cell competition detected in all outcompeted
cells, whereas Caspase activation is a late event detected only in
a few cells at a given time.
Next, we studied how dSPARC expression in the supercom-
petitor assay is affected by manipulations of upstream events
of cell competition such as imbalances in morphogen and
survival factor signaling. Because loser wt cells have a deficit
in survival signaling compared to dMyc-overexpressing super-
competitors (Moreno et al., 2002a; Moreno and Basler, 2004),
we overexpressed several survival factors and/or morphogens,
including Dpp, Wingless, and the Insulin-receptor specifically
in loser cells. Consistent with previous results, UAS-Dpp overex-
pression significantly rescued the elimination of wt loser cells
(Moreno and Basler, 2004) and repressed dSPARC activation
(Figures 3G and 3H). In contrast, wt loser cells overexpressing
Wingless and Insulin-receptor driven by UAS still showed high
levels of dSPARC protein (Figures 3I–3L).
Because cell competition can trigger JNK activation in the
loser cells (Moreno et al., 2002a), we also tested if dSPARC
upregulation depends on the activation of the JNK pathway.
We blocked JNK activity specifically in the loser cells using the
JNK phosphatase puckered (puc) (Martı´n-Blanco et al., 1998)
or a dominant negative form of the Drosophila JNK Basket (Glise
and Noselli, 1997) specifically in loser cells with UAS transgenes
(Figures 3 M–3P). Inactivation of the JNK pathway did not
repress dSPARC upregulation despite it rescued cell death as
previously shown (Moreno et al., 2002a; Moreno and Basler,
2004).
From the above experiments we conclude that dSPARC acts
downstream of Dpp and that the enhancement of dSPARC
expression during cell competition occurs independent of JNK
signaling.
dSPARC Protects Loser Cells during Cell Competition
To functionally analyze the role of dSPARC, we decided to use
specific dsparc RNAi lines (Dietzl et al., 2007), which permits to
study the reduction of the extra dSPARC produced by the loser
cells (Figures S2A–S2C). The three RNAi lines used (from two
different collections, KK and GD) have one possible off-target
by sequence homology, CG11874, which is a gene of unknown
function. We found that CG11874 is expressed in the imaginal
discs, but its expression is not affected by dsparc RNAi, sug-
gesting that the RNAi lines only target dsparc (Figures S2D–
S2F). When UAS-RNAi dsparc was activated in loser cells inental Cell 19, 562–573, October 19, 2010 ª2010 Elsevier Inc. 565
Figure 3. Epistasis Analysis
(A and B) In situ hybridization reveals the presence of dsparc mRNA (red) in wt clones (green) in a tub > dmyc background.
(C–F) Neither expression of p35 (C) nor dIAP1 (E) can downregulate dSPARC expression (red) in loser cells, even though they are rescued from cell competition
(72 hr ACI). Quantitation of dSPARC levels in loser cells did not show significant differences between the experiments shown in Figures 1G and 1H and those from
Figures 3C–3F (not shown).
(G and H) The overexpression of Dpp specifically in loser cells prevents dSPARC upregulation (G), whereas overexpression of InR (I and J) orWg (K and L) do not
(48 hr ACI). Expression of UASpuc (M and N) or a dominant negative form of bsk (UASbskDN) (O and P) in loser cells (green) does not suppress dSPARC upre-
gulation (red), even though loser cells are rescued from cell competition (72 hr ACI).
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dSPARC Protects Loser Cells from Cell Competitionthe supercompetitor assay, the majority of those cells were
eliminated, and the clones were strongly reduced in size at
48 hr ACI, whereas loser cells with intact dsparc levels showed
this effect only at 72 hr ACI (Figures 4A–4D and 4G). Activation
of UAS-RNAi dsparc in control clones (using tub > CD2 > Gal4
or actina1 > yellow > Gal4 flies) did not affect survival of the
dsparc RNAied cells surrounded by wt cells (no RNAi) (Fig-
ure 4D0). We obtained similar data for all three dSPARC RNAi
lines of the KK andGD collection (Figures S2G–S2O). In addition,
when we generated GFP-marked wt loser cells in a tub > dmyc
background but in a disc heterozygously mutant for a deletion
in dsparc (Df(3R)nm136 [Martinek et al., 2008]), wt clones were
outcompeted faster compared to the control (Figures S2G–
S2M), similar to the dsparc RNAi data. This raised the possibility
that dSPARC extra-production could be actively protecting loser
cells during cell competition. Alternatively, the faster elimination
of dsparc RNAied loser clones could be merely due to a cell-566 Developmental Cell 19, 562–573, October 19, 2010 ª2010 Elsevautonomous additive effect (i.e., reducing dSPARC in already
weakened cells due to cell competition).
To further investigate whether dSPARC in loser cells could
serve as a protective signal, which partially delays the elimination
of outcompeted cells, we decided to overexpress dsparc in loser
cells by generating an untagged and a C-terminally HA-tagged
UAS-dsparc construct (Figures S2P–S2S). Experiments with
such transgenic flies should reveal whether dSPARC overex-
pression is sufficient to protect loser cells from being outcom-
peted in a dose-dependent manner. When UAS-dsparc or
UAS-dsparc-HA was activated specifically in the loser wt cells
surrounded by tub > dmyc supercompetitors, apoptosis was
reduced and cell competition prevented (Figures 4E–4G). Over-
expression of dsparc rescued cell elimination even better
than overexpression of p35 (Figure 4G). This is a stringent assay
because few factors are able to rescue the elimination of
loser cells during cell competition. Based on these results weier Inc.
Figure 4. Overexpression of dSPARC Rescues wt Cells from Cell Competition
(A) GFP-marked wt cells (green) in a tub > dmyc supercompetitor background 48 hr and (B) 72 hr ACI. wt loser cells are gradually outcompeted, first in the wing
pouch until only a few clones remain in the periphery of the disc.
(C) RNAi of dsparcGD (Chr 3) specifically expressed in loser cells marked by GFP leads to a faster reduction of loser clones (green) at 48 hr and (D) 72 hr ACI
compared to wt cells (A and B, respectively). (D0) Control wt clones expressing RNAi of dsparc (green).
(E) Overexpression of dsparc specifically expressed in the losers, which are marked by GFP (using a UAS-dsparc transgene), rescues the elimination of loser
clones (green) by tub > dmyc supercompetitors at 48 hr ACI (E) and 72 hr ACI (F).
(G) Quantification of remaining loser clones in the supercompetitor assay at various time points ACI; the number of animals analyzed is indicated (n). Error bars
represent SD. The asterisks indicate statistical significance in a Student’s t test.
(H) Loser clones (green) in a tub > dmyc background 72 hr ACI expressing a UAS-p35 transgene.
(I) Caspase-3 staining is shown in red.
(J) Loser clones (green) in a tub > dmyc background expressingUAS-dsparc at 72 hr ACI. In this case, Caspase 3 activation is prevented. Note the absence of red
apoptotic cells (K).
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dSPARC Protects Loser Cells from Cell Competitionconclude that dSPARC is sufficient to act as a protective signal in
loser cells.
At which level of the multistep process of cell competition is
dSPARC acting as a protective signal? dSPARC overexpression
or RNAi neither affected dMyc expression nor Dpp signal-
ing (pMad) (Figures S2T–S2W). Furthermore, dSPARC-overex-
pressing cells that were confronted with tub > dmyc supercom-
petitors survived and did not show any signs of Caspase
activation, whereas p35 overexpression blocks cell death but
does not prevent Caspase activation (Figures 4J and 4K,
compare it with Figures 4H and 4I), proving that high levels of
dSPARC are not only necessary but sufficient to interrupt the
process before Caspase activation, and, therefore, upstream
engulfment (Li and Baker, 2007) and/or basal extrusion (Moreno
and Basler, 2004). These epistasis experiments suggest thatDevelopmdSPARC acts downstream of survival factor withdrawal but
upstream of Caspase activation.dSPARC Does Not Generally Protect from Apoptosis
To test whether dSPARC could function as an inhibitor of
apoptosis in other contexts, we coexpressed egr and dsparc
under the control of the eye-specific gmr promoter (Figures 5A
and 5B), which triggers apoptosis in cells posterior to the
morphogenetic furrow (Igaki et al., 2002; Moreno et al., 2002b).
We compared the eye size of these flies with flies that only
express egr (Figure 5A), with flies that coexpress egr and
dIAP1 (Figure 5C), and flies that coexpress egr and the egr
RNAi (Figure 5D) (that have a wt eye), and we observed that
dsparc is not able to block or suppress the eye eliminationental Cell 19, 562–573, October 19, 2010 ª2010 Elsevier Inc. 567
Figure 5. dSPARC Is Not a General Inhibitor of Apoptosis
(A–E) egr is ectopically expressed in the eye under the gmr promoter where it induces cell death and causes eye ablation (A). Coexpression of egr and dsparc does
not block or suppress the eye elimination phenotype (B). Coexpression of egr and dIAP1 partially suppresses the eye elimination phenotype (C). Coexpression of
egr and the egr RNAi rescues the eye elimination phenotype (D).
(E) Quantification of the eye area for all genotypes; the number of animals analyzed is indicated (n). Error bars represent SD. The asterisks indicate statistical
significance p < 0,0001 in a Student’s t test (n.s., not significant).
(F)wtmale with its ventral side up, showing the correct position of external terminalia (analia plus genitalia). The positions of the genitalia and analia are indicated.
(G) If developmental cell death is inhibited in the male terminalia (in en-Gal4; UASp35 flies), the flies show a failure in the rotation of the analia and genitalia
compared to the wt.
(H) Males overexpressing dSPARC in the terminalia (en-Gal4; UASdsparc) show a normal arrangement of the terminalia.
(I–N) lacZ as a control, dIAP1 and dsparc are ectopically expressed in the dorsal compartment of the wing pouch driven by ap > Gal4 (green). Active Caspase 3 is
shown in red. Apoptosis is inhibited by dIAP1 (compare I and L with J and M). The Caspase 3 activation in discs with dorsal dsparc overexpression (K and N) is
similar to a wt disc (I and L).
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dSPARC Protects Loser Cells from Cell Competitionphenotype induced by egr (Figures 5A–5E). Because the assay
that we used to investigate dSPARC’s ability to inhibit cell death
was performed in a scenario of catastrophic cell death induced
by overexpression of pro-apoptotic factors, we decided to
examine the effect of dSPARC overexpression in more physio-
logical cell death scenarios, such as developmental apoptosis568 Developmental Cell 19, 562–573, October 19, 2010 ª2010 Elsevinvolved in the terminalia rotation ofDrosophilamales. The termi-
nalia is composed of two fused segments, the genitalia (Estrada
and Sa´nchez-Herrero, 2001) and the analia (Moreno andMorata,
1999) that rotate together. It has been shown that terminalia rota-
tion requires cell death and that it can be blocked by inhibition or
reduction of apoptosis, for example using the Caspase inhibitorier Inc.
Figure 6. dSPARC Protein Protects S2 Cells
from a ‘‘Killing Signal’’
(A) Western blot with proteins from dSPARC-HA
transfected S2 cells and respective supernatants.
dSPARC-HA protein can be detected with an
anti-HA antibody (red band, arrowhead). Tubulin
(green) is used as a loading control. Protein com-
plexes including dSPARC-HA are found in the
supernatant fractions (red band, arrow).
(B–F) (B) S2 cells grown in the presence of 10%
serum, (C) in serum-free media, (D) transfected
with dSPARC-HA and serum deprived, (E) serum-
deprived S2 cells complemented with dSPARC
enriched supernatant (from D), and (F) same as
(E) plus specific anti-dSPARC antibody.
(G) Cell survival is plotted after different treat-
ments: Serum or KS. Tf, transfected. Sp, superna-
tant. Ab, dSPARC antibody. Error bands represent
SD, n = 3.
(H and I) Endogenous dSPARC expression in S2
cell cultivated in 10% serum (H) or under serum
deprivation (I).
(J) Western blot with proteins from S2 cells culti-
vated in 10% serum or under serum deprivation;
endogenous dSPARC protein is upregulated in
serum-deprived conditions. dSPARC protein was
detected with anti-dSPARC antibody and tubulin
is used as a loading control.
(K–M) (K) S2 cells after 36 hr in KS-enriched
medium (supernatant from 6C + 10% serum,
see Experimental Procedures). (L) KS-enriched
medium supplemented with dSPARC supernatant
(from D). (M) KS-enriched medium supplemented
with 150 ng/100 ml dSPARC-purified protein. The
S2 cells in B–F and K–M are stained with phalloidin
(green) to visualize the cell shape and DAPI (blue)
to mark the nuclei.
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dSPARC Protects Loser Cells from Cell Competitionp35 (Figures 5F–5H) (Macias et al., 2004) or mutants for the
pro-apoptotic factor hid (Abbott and Lengyel, 1991; Macias
et al., 2004). We observed that, unlike general inhibitors of devel-
opmental apoptosis, the overexpression of dsparc in the genital
disc using the en-gal4 driver gives rise to awt terminalia (Figures
5F–5H), showing that it does not block this apoptosis-dependent
developmental process. We also checked the random apoptosis
in wing imaginal discs. ap-gal4/+ imaginal discs show random
apoptosis in the wing pouch that is higher in the dorsal region
of the developing wing (Figures 5I and 5L), but that does not
seem to affect the morphology of the adult because those wings
are morphologically normal (Calleja et al., 1996). Overexpression
of dIAP1was able to block this apoptosis (Figures 5J and 5M) but
dSPARC was not (Figures 5K and 5N). These data, together with
the fact that dSPARC does not prevent X-ray induced Caspase
activation (Figure S3), suggest that dSPARC is not a generalDevelopmental Cell 19, 562–573,inhibitor of apoptosis, despite its potent
inhibition of cell competition-induced cell
death (Figure 4).
dSPARC Protein Protects S2 Cells
from a ‘‘Killing Signal’’
We next sought to uncover how upregu-
lated dSPARC works to buffer survivalfactor deficits in outcompeted cells. First, we tested if
dSPARC-HA is secreted in Drosophila (S2) cells. Expression of
HA-tagged dSPARC resulted in the presence of the protein in
both cellular and supernatant extracts, confirming the function-
ality of the secretion signal (Figure 6A). To evaluate a protective
role of dSPARC after survival factor withdrawal, S2 cells were
transiently transfected with either dsparc or GFP and, after
48 hr, serum was removed from the medium; cell survival and
apoptosis were measured 24 hr later. After serum deprivation
only 40% of the cells expressing GFP survived (Figures 6B,
6C, and 6G), whereas 95% of the cells in the well transfected
with dsparc survived after the same treatment (Figures 6D
and 6G).
Because dSPARC is secreted into the medium, we tested
whether the presence of dSPARC protein in the supernatant
could confer some protection to wt S2 cells after serumOctober 19, 2010 ª2010 Elsevier Inc. 569
Figure 7. dSPARC and Fwe Belong to Different Pathways in Cell Competition
(A and B) Expression of fwe RNAi specifically in GFP-marked wt cells (green) surrounded by tub > dmyc supercompetitors. The downregulation of fwe does not
interfere with the upregulation of dSPARC upon supercompetition (red).
(C and D) In situ hybridization reveals the presence of fweLose-A mRNA (red) inwt clones that ectopically overexpress dsparc (green) in a tub > dmyc background.
Negative control with fweLoseA sense probe for the in situ hybridization (E and F).
(G and H) wt clones that overexpress fweLose-A are marked with GFP (green) in a wt background do not show changes in dSPARC levels (red).
(I and J) wt clones overexpressing fweLose-B (green) in a wt background do not show changes in dSPARC expression (red).
(K–M) fwe mutant clones (absence of green) do not show altered dSPARC expression (red).
(N) dsparc and fwe both play a role during cell competition in the loser cells, but they act in independent pathways (SF, survival factors).
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dSPARC Protects Loser Cells from Cell Competitiondeprivation. The addition of conditioned, serum-free medium
from dSPARC-transfected cells resulted in a significant
protection of serum-deprived wt cells (Figures 6E and 6G);
this protection was reverted when anti-dSPARC antibody
was added to such medium (Figures 6F and 6G). Similar to
outcompeted cells in the imaginal discs, S2 cells upregulated
dSPARC upon serum deprivation, as detected by increased
signal in immunohistochemistry (Figures 6H and 6I). Western
blot analysis performed with S2 cell lysates before and after
serum withdrawal confirmed that dSPARC protein levels rise
markedly following serum withdrawal (Figure 6J). These
results suggest a protective effect for the secreted form of
dSPARC.570 Developmental Cell 19, 562–573, October 19, 2010 ª2010 ElsevIn order to find out the mechanism of action of dSPARC, S2
cells were serum deprived for 24 hr, and when they started to
die, the conditioned supernatant of these cells was collected
(KS medium). When added to healthy S2 cells, the KS medium
induced cell death in the absence of serum deprivation (Fig-
ure 6K), suggesting that at least one secreted KS is present.
To test whether secreted dSPARC can inactivate the KS, we
combined the KS medium with the supernatant of cells trans-
fectedwith the dsparc plasmid, and the reversion of the KS effect
was indeed observed (Figure 6L). Importantly, even when the
same KS medium was added to healthy S2 cells, together with
purified dSPARC protein, cell survival increased (Figure 6M).
All these findings indicate that the KS is a secreted molecule.ier Inc.
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in Cell Competition
Next, we wanted to test whether there is any relationship
between dSPARC and Fwe because both have specific func-
tions during cell competition (Rhiner et al., 2010) and could be
part of the same pathway.
First, we used the supercompetitor assay and expressed fwe
RNAi in wt loser cells (green) in a tub > dmyc background; we
observed that knock-down of all the Fwe isoforms did not inter-
fere with dSPARC upregulation in loser cells during cell competi-
tion (Figures 7A and 7B). Next, we overexpresseddsparc, in addi-
tion to the upregulation of the endogenous dSPARC, in
GFP-marked wt loser cells in a dmyc-overexpressing back-
ground and performed in situ hybridization with fweLose-A mRNA
probe. We found that fweLose-A upregulation is not affected by
additional overexpression of dSPARC during cell competition
(Figures 7C–7F). Because it is known that the overexpression of
fweLose isoforms induces apoptosis (Rhiner et al., 2010), we
generated wt clones that overexpress UAS-fweLose-A or UAS-
fweLose-B in a wt background, where no competition takes place
(Figures 7G–7J). We observed that the endogenous levels of
dSPARC did not change in the entire disc, and there was also no
upregulation of dSPARC in the fweLose- overexpressing clones.
Finally, we generated fwe mutant clones that are eliminated due
to the lack of fweubi (Rhiner et al., 2010) and could not detect any
altereddSPARCexpression insuchclones (Figures7K–7M).These
results suggest that dSPARC and Fwe function in parallel path-
ways and have opposing roles during cell competition (Figure 7N).
DISCUSSION
In summary, we describe here the existence of a physiological
mechanism that counteracts cell competition. We provide
evidence that dSPARC is a specific marker of cell competition,
and not a general marker of apoptosis. Transcriptional activation
of dsparc sets a higher threshold for Caspase activation in loser
cells, possibly by inactivating an unknown secreted KS, which is
produced upon survival factor withdrawal. We further show that
dSPARC is not a general inhibitor of apoptosis, despite its potent
inhibition of cell competition-induced cell death. dSPARC may
allow useful cells to recover from transient and limited damage
before they are unnecessarily eliminated by their neighbors.
Our results show that dSPARC and Fwe function in parallel
and opposing pathways during cell competition, with dSPARC
providing transient protection, whereas the ‘‘Fwe Code’’ pro-
motes cell elimination by labeling cells as ‘‘losers’’ (Rhiner
et al., 2010). Therefore, it seems likely that during early stages
of cell competition, the decision of whether the potential loser
cell will finally undergo apoptosis or not is still reversible. This
intermediate state, where dSPARC protects outcompeted cells,
mayprevent the removal of valid cells that suffer only a temporary
fitness deficit. However, if the differences in cellular fitness
persist and/or are too ample, cell competition-induced apo-
ptosis is, nevertheless, triggered.
One possibility is that secreted dSPARC blocks the unknown
KS(s) directly in the extracellular space. dSPARC could bind
directly to the KS(s) or just form a matrix that serves as a barrier
for the KS(s) to reach the loser cells. The other possibility is that
dSPARC could activate a protective pathway in an autocrineDevelopmway that counteracts the effects of theKS. For example,mamma-
lianSPARChasbeenshown toprotect cells fromapoptosis invitro
via activation of integrin-linked kinase and AKT (Weaver et al.,
2008; Shi et al., 2004). Whether the KS(s) is the same as the one
proposed previously (Senoo-Matsuda and Johnston, 2007) is
unclearbecause,unfortunately,wewereunable to reproduce their
results in our laboratory (S.C.-T. and E.M., unpublished data).
We describe a physiological process that counteracts cell
competition and that relates dSPARC to cell competition. If cell
competition is conserved in mammals, as mounting evidence
suggests (Bondar and Medzhitov, 2010; Oertel et al., 2006;
Oliver et al., 2004; Sansom et al., 2007; Tamori et al., 2010),
this role of dSPARC specifically repressing cell competition
may have important consequences for our understanding of
mammalian development, homeostasis, stem cell replacement,
or cancer. In particular, deregulation of this mechanism is likely
to be important in cancer (Moreno, 2008; Vidal and Cagan,
2006; Tamori et al., 2010; Bondar and Medzhitov, 2010), for
example by allowing metastatic cells to survive in a new environ-
ment or during the expansion of cancerization fields.
EXPERIMENTAL PROCEDURES
In Situ Hybridization
To determine whetherCG6378 (dsparc) was expressed in loser or winner cells,
mRNA FISHwas performed as previously reported (Rhiner et al., 2010). Probes
were generated using the following primers:
CG6378 SP6: 50ATTTAGGTGACACTATAGAAGAGTCTGCACCAATACCAA
CGAG 30 and CG6378 T7: 50TAATACGACTCACTATAGGGAGACGATGGTCC
TTGTTGGAGTC 30.
Primers to generate the probe to detect fweLose-A expression were the
following:
fweLose-A SP6: 50ATTAGGTGACACTATAGAAGAGGCTTCTCGAGAGGACA
TGG 30 and fweLose-A T7: 50TAATACGACTCACTATAGGGAGAGGCGCCAGA
CATCGG 30.
Cell Culture and Transactivation Assays
The plasmid acta1 >Gal4 (gift of K. Basler) was used in the transfections to acti-
vate theUAS constructs.dsparc cDNAswere cloned into KpnI and XbaI restric-
tion sitesofpUASp in framewithaC-terminalHAepitopeorwithout tag, yielding
the expression construct pUAS-dsparc-HA and pUAS-dsparc. The pUAST-
GFP vector was used as control. The 1.53 106 S2 cells were transfected with
SuperFect (QIAGEN) using 0.2 mg DNA from each construct. Cells were treated
with PBS/NaCl 150 mM/Triton 1% buffer to extract proteins.
For serum deprivation and KS experiments, cells were cultured in
Schneider’s medium (Sigma) 10% serum fetal bovine and antibiotics (penicillin
and streptomycin) in 75 cm3 flasks for 24 hr. Medium was substituted with
serum-free medium (Grace’s insect media [Lonza]), and cells were maintained
for a further 24 hr. Then, supernatant was recovered and complemented with
10% serum, which was termed KS medium.
For immunostaining, transfected cells were fixed and then stained with
mouse anti-dSPARC (1:10) or rat anti-HA antibody (1:500) (Roche), phalloidin
Alexa fluor 488 (Invitrogen), and fluorescence-coupled secondary antibodies
(1:250; Invitrogen). Cells were mounted in Vectashield with DAPI.
For western blots, we used NuPAGE Bis-Tris Gels 4%–12% (Invitrogen) and
the following primary antibodies: rat anti-HA antibody (1:5,000) (Roche),
mouse anti-tubulin (1:1,000,000) (Sigma), and rabbit anti-dSPARC antibody
(1:5,000) (a gift from Martinek N).
wt Clones in tub > dmyc Background-Expressing Effector
Transgenes and Mitotic Recombination Clones
The fly stocks used were obtained from the Bloomington Stock Center except
where indicated. To generate wt clones in tub > dmyc background expressing
different UAS constructs, crosses were performed as previously described
(Moreno and Basler, 2004). The following stocks were used: UAS-p35,ental Cell 19, 562–573, October 19, 2010 ª2010 Elsevier Inc. 571
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dSPARC Protects Loser Cells from Cell CompetitionUAS- dIAP1, UAS-Dpp, UAS- LacZ, UAS-wg-HA, UAS-InR, UAS-puc, UAS-
RNAi egr, UAS-bskDN, and w;H2Av-GFP Df(3R)nm136 (Martinek et al.,
2008). The larvaewere subjected to a 15min heat shock at 37Cand harvested
48 and 72 hr ACI.
For RNAi experiments the following stocks of the VRDC center were used:
UAS-RNAi dsparc (ID 16677, Chr 2, viable), UAS-RNAi dsparc (ID 16678,
Chr 3, viable), UAS-RNAi dsparc (ID 100566, Chr 2, viable), UAS-RNAi fwe
(ID 39596, Chr 2, viable), UAS-RNAi fwe (ID 104993, Chr 2, viable) and UAS-
RNAi egr (ID 45253, Chr 3, viable). Multiple UAS-dsparc and UAS-dsparc-
HA transgenic lines for overexpression experiments were generated by
standard methods. For the generation of mitotic recombination clones,
the following stocks were used: ywhs-FLP; FRT82B arm-lacZ/TM6b, ywhs-
FLP; FRT82B ubi-GFP M (3L)RpS3, ywhsf, tub-gal4 UAS-GFP/FM7; ubi-
Gal80FRT40/CyO, lgl4 FRT40/ CyO, ywhsf; FRT40 ubi-GFP/CyO, PTEN100
FRT40/CyO, ywf;Sp/CyO; ubi-GFP FRT80B/TM6b and fwe202 FRT80B/
TM6b. To generate wt clones in a wt background, the following stocks were
used: ywf; sp/CyO; Pact > y > gal4 UAS-GFP/TM6b (a gift of R. Mann),
UAS-brk, UAS-hepCA, w;UAS-HA-egr (M. Miura), UAS-fweLose-A, UAS-
fweLose-B, UAS-hid (H. Steller), ywf, Pact > CD2 > gal4 UAS-GFP; Gal80ts/
TM6b. For the eye phenotype the following stocks were used: gmr-Gal4
UAS-egr/CyO, UAS-LacZ, UAS-dsparc, UAS-dIAP1 and UAS-RNAi egr II.
For the terminalia study the following stocks were used: en-Gal4 II, UAS-
lacZ, UAS-dsparc, and UAS-p35.
The following driver lines were used in this study: ap-Gal4 UAS-GFP/CyO,
en-Gal4 UAS-GFP/CyO, da-Gal4, and gmr-Gal4 UAS-egr/CyO.
Quantifications
The areas occupied by GFP-positive clones and the wing pouch areas were
quantified in all the discs using Metamorph 7.0 (Molecular Devices). Averages
and the standard deviation (SD) were calculated for each time point (24, 48,
and 72 hr). All error bars represent SD. Statistical significance was calculated
with the Student’s t test.
The eye area was quantified using Image-J A 1.44a software.
Apoptotic corpses in discs containing dSPARC-overexpressing clones in
a dMyc-overexpressing background were counted by Metamorph 7.0 (Molec-
ular Devices).
dSPARC Antibody and Immunofluorescence
A mouse monoclonal antibody against the peptide EAETNNSRRWSNAA
VWKWC of dSPARC was generated by standard methods.
Imaginal discs were fixed and incubated with mouse (1:10) or rabbit (1:500)
anti-dSPARC, followedbysignalamplificationwith tyramide (Invitrogen).Further
antibodies used for immunohistochemistry were as follows: rabbit anti-GFP
(1:250) (Invitrogen), mouse anti-GFP (1:250) (Roche), rabbit anti-pMad (1:400)
(G. Morata), mouse anti-dMyc (R.N. Eisenman and B.A. Edgar), rabbit anti-
cleavedCaspase-3 (Cell SignalingTechnology), rat anti-HA (Roche), andmouse
anti-Wg (DSHB). All images were obtained with a LEICA TCS-SP2-AOBS.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at doi:10.1016/
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